About Ankylosing Spondylitis Ankylosing spondylitis is a subtype of spondylarthropathy. The primary symptoms of the disease are inflammatory spinal pain with subsequent limitation of spine mobility and chest expansion. Ankylosing spondylitis can be diagnosed using clinical signs, radiological signs (sacroiliitis) and the presence of HLA-B27 antigen. According to the NIH and NIAMS, ankylosing spondylitis is a type of arthritis, which affects the joints in the vertebral column severely. It is a progressive inflammatory disease that typically becomes evident during early to mid-adulthood, as per NORD. It can also lead to the loss of spinal mobility for the affected individuals. The cause of the disease is not known, however, the HLA-B27 gene plays a major role. Ankylosing spondylitis is hereditary in nature. TechNavio's analysts forecast the Global Ankylosing Spondylitis market to grow at a CAGR of 5.05 percent over the period 2014-2019.
Covered in this Report This report covers the present scenario and the growth prospects of the Global Ankylosing Spondylitis market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of ankylosing spondylitis. The market is segmented based on the mechanism of action of the drugs used to treat ankylosing spondylitis as illustrated below: • TNF Inhibitors • COX Inhibitors • Others On the type of molecule used for the treatment of ankylosing spondylitis, as illustrated below: • Biologics • Small Molecules On the basis of route of administration adopted for the treatment of ankylosing spondylitis, the Global Ankylosing Spondylitis market is segmented as follows: • Oral • Parenteral In addition, the market is also bifurcated on the basis of dosage forms of the drugs used in the treatment of the disease: • Solid • Liquid The report also presents the vendor landscape and a corresponding detailed analysis of the top five vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, it discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market. Also, the late-stage pipeline molecules developed for the treatment of Ankylosing Spondylitis have been discussed. TechNavio's report, Global Ankylosing Spondylitis Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC region and the EMEA; it also covers the Global Ankylosing Spondylitis market landscape and its growth prospects in the coming years. The report also includes a discussion on the key vendors operating in this market.
Market Driver • Presence of Unmet Need • For a full, detailed list, view our report
Market Challenge • Threat from Patent Expiry • For a full, detailed list, view our report
Market Trend • Market Dominance by Biologics • For a full, detailed list, view our report
Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors?
Our reports have been used by over 10K customers, including:
Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease - Drugs in Development, 2021, provides an overview of the Non Alcoholic Fatty Liver Disease (Gastrointestinal)...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
Patient history: The industry will likely benefit from new-and-improved service capability advances Abstract Diagnostic & Medical Laboratories in the US Operators in the Diagnostic and Medical Laboratories industry are an integral part of patients’ medical evaluation and treatment. Laboratories are...
Melanoma - Global Drug Forecast and Market Analysis to 2029
Melanoma of the skin is a serious and aggressive form of cancer originating from melanocytes, the pigment cells in skin, and can develop anywhere on the body.Although melanoma has high survivability, it remains a significant health...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
Pulmonary Arterial Hypertension - Global Drug Forecast and Market Analysis to 2029
Pulmonary arterial hypertension is a rare, fatal cardiopulmonary disease with an annual mortality rate around 10%.The disease is a subset (Group 1) within the World Health Organization’s (WHO’s) classification...
Executive Summary The global radiation therapy market was valued at USD 5216.04 million in the year 2019, according to a research report published in June 2020. The growth of the radiation therapy market will primarily be supported by an Increasing public health spending as cancer is the second most deadly disease in the...
Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development. - Globally,...
Cancer rates could further increase by 50%, to 15 million new cases, by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners can prevent as many as one-third of cancers, worldwide. The American Cancer...
Research And Development
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.